Indian Biosimilars: Going Global
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Address: 142 AB, Kandivli Co-operative
Industrial Estate Ltd.,
Kandivli (West),
Mumbai – 400 067. Maharashtra,India
Tel: +91 (022) 6647 4747
Ipca is a fully integrated, rapidly growing Indian pharmaceutical company with a strong thrust on exports. Ipca’s APIs and Formulations produced at worldclass manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA). With operations in over 100 countries, exports account for over 52% of the company’s income.
Forbes, a leading US business magazine, selected Ipca in 2003 among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion. Over 19,000 companies were considered by Forbes, and of the 18 companies from India that figured in this list, only four were from the ‘Indian Pharmaceutical Sector’. Ipca happens to be one of them. Subsequently, Ipca was selected by FORBES in this prestigious list for two consecutive years; 2004 and 2005.
From a modest income of Rs. 0.54 crores in 1975-76, the net income has soared to Rs. 753.30 crores in 2005-06 with exports accounting for Rs. 401.83 crores. The net profit for the year ending 31st March, 2006 stood at Rs. 63.98 crores. Formulations constitute 67 percent of the total income for 2005-06. Today, Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over.
Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in…
Alexandre Williams, founder and managing director of Athena, an international company with an Indian manufacturing basis specialized in life cycle products, provides insights into some key trends shaping India’s pharmaceutical…
As the founder and chairman of Alves Group, a key Indian player in medical devices with an extensive portfolio, Randolph Alves shares the challenges India needs to overcome to remain…
Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main…
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’…
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
See our Cookie Privacy Policy Here
